this is a very good sign in my opinion. I would very much like to know exactly when IMM submitted the request for the C-type meeting with the FDA. The meeting has to be scheduled within 75 days of the request. I suspect IMM will request that PFS be approved as a surrogate endpoint, which has precedence, with OS as a confirmatory indicator. Both readings are very strong for the trial. There is low adverse events and it is a high unmet need. If they accept the surrogate endpoint, accelerated approval is next. It is looking very good from my perspective. This is in HNSCC with negative PD-1 of course.
IMM Price at posting:
25.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)